Ocular myasthenia gravis: Predictive value of single fiber electromyography

被引:1
作者
Weinberg, DH [1 ]
Rizzo, JF
Hayes, MT
Kneeland, MD
Kelly, JJ
机构
[1] St Elizabeths Med Ctr, Dept Neurol, Boston, MA 02135 USA
[2] Tufts Univ, Sch Med, Boston, MA 02135 USA
[3] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA
[4] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA
[5] St Elizabeths Med Ctr, Dept Med, Boston, MA 02135 USA
[6] George Washington Univ, Med Ctr, Dept Neurol, Washington, DC 20037 USA
关键词
myasthenia gravis; ocular; generalized; single-fiber electromyography; prognosis;
D O I
10.1002/(SICI)1097-4598(199909)22:9<1222::AID-MUS8>3.3.CO;2-I
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Extraocular muscle weakness is the most common presenting sign of myasthenia gravis (MG). More than half of patients presenting with symptoms isolated to these muscles (OMG) develop generalized myasthenia gravis (GMG) over the course of their illness, No clinical, laboratory, or electrophysiological features are recognized that identify these highrisk patients. We have therefore assessed the ability of single-fiber electromyography (SFEMG) to predict the development of GMG in patients presenting with OMG. Thirty-nine consecutive patients presenting with OMG underwent SFEMG of the extensor digitorum communis muscle as well as a battery of other laboratory and imaging studies at the time of diagnosis. Ail patients were followed prospectively for a minimum of 24 months or until they developed GMG. Two patients were excluded, leaving 37 for assessment. Twenty remained with pure OMG for the entire follow-up period (mean, 55 months). Twenty-six of the 37 had abnormal SFEMG studies at presentation. Eleven of these remained with OMG and 15 developed GMG. Fifty-eight percent of patients with an abnormal SFEMG developed GMG, whereas 82% of those with a normal study remained with OMG. Thus, a normal SFEMG was associated with MG remaining restricted to the extraocular muscles. (P = 0.036, Fisher's exact test), but an abnormal SFEMG was not predictive of subsequent development of GMG. (C) 1999 John Wiley & Sons, Inc.
引用
收藏
页码:1222 / 1227
页数:6
相关论文
共 30 条
[1]   Myasthenia gravis: Diagnosis and follow-up of 100 consecutive patients [J].
Beekman, R ;
Kuks, JBM ;
Oosterhuis, HJGH .
JOURNAL OF NEUROLOGY, 1997, 244 (02) :112-118
[2]   PROGNOSIS OF OCULAR MYASTHENIA [J].
BEVER, CT ;
AQUINO, AV ;
PENN, AS ;
LOVELACE, RE ;
ROWLAND, LP .
ANNALS OF NEUROLOGY, 1983, 14 (05) :516-519
[3]   CRITICAL-ASSESSMENT OF LOCAL CURARE TEST IN MYASTHENIA-GRAVIS [J].
BOIARDI, A ;
BUSSONE, G ;
NEGRI, S .
EUROPEAN NEUROLOGY, 1977, 15 (05) :275-280
[4]   SINGLE-FIBER EMG REFERENCE VALUES - REFORMATTED IN TABULAR FORM [J].
BROMBERG, MB ;
SCOTT, DM .
MUSCLE & NERVE, 1994, 17 (07) :820-821
[5]   ELECTROPHYSIOLOGICAL INVESTIGATION OF NEURO-MUSCULAR TRANSMISSION IN MYASTHENIA GRAVIS [J].
ELMQVIST, D ;
KUGELBERG, J ;
HOFMANN, WW ;
QUASTEL, DMJ .
JOURNAL OF PHYSIOLOGY-LONDON, 1964, 174 (03) :417-&
[6]  
EMERYK B, 1990, Electromyography and Clinical Neurophysiology, V30, P53
[7]   ORAL CORTICOSTEROIDS IN TREATMENT OF OCULAR MYASTHENIA-GRAVIS [J].
FISCHER, KC ;
SCHWARTZMAN, RJ .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1976, 274 (MAY28) :652-658
[8]   CLINICAL-EXPERIENCE IN MORE THAN 2000 PATIENTS WITH MYASTHENIA-GRAVIS [J].
GENKINS, G ;
KORNFELD, P ;
PAPATESTAS, AE ;
BENDER, AN ;
MATTA, RJ .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1987, 505 :500-514
[9]  
GILCHRIST JM, 1992, MUSCLE NERVE, V15, P151
[10]   THE COURSE OF MYASTHENIA-GRAVIS AND THERAPIES AFFECTING OUTCOME [J].
GROB, D ;
ARSURA, EL ;
BRUNNER, NG ;
NAMBA, T .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1987, 505 :472-499